Get to work

Houston becomes job capital of Texas with highest number of openings in the state

New study shows Houston has more job openings than any other Texas city. Photo by Tim Leviston/Getty Images

As all good Houstonians know, the Bayou City reigns as the energy capital of the world. But, as it turns out, Houston also ranks as the job capital of Texas.

In October, a daily average of 4,188 job openings were listed in Houston — more than any other place in Texas. That's according to a review by data-mining company Thinkum of online job postings at thousands of companies.

In terms of the sheer number of daily job postings, Houston ranked fifth among U.S. cities in October, according to Thinkum. Seattle held the No. 1 spot (10,291 average daily job listings).

Thinkum's top 20 also included Austin (No. 6), with a daily average of 3,227 job postings, and Dallas (No. 12), with 2,685.

The abundance of job listings in Houston can be attributed, in part, to its status as one of the top U.S. metro areas for corporate relocations and expansions, as ranked by Site Selection magazine. In 2017, the Houston welcomed 196 new and expanded corporate facilities.

"Houston is the most diverse city in the U.S. and companies thrive in our region. We are powered by a highly skilled and well-trained talent base that enjoys an excellent quality of life," Bob Harvey, president and CEO of the Greater Houston Partnership, said in March.

Career website LinkedIn says hiring in the Houston metro area climbed 14.3 percent in September 2018 compared with September 2017. On a seasonally adjusted basis (removing predictable variations for seasonal hiring), hiring went up 0.8 percent from August to September, according to LinkedIn.

That's good news for the Houston area, as the unemployment rate in September was 4.1 percent, according to the U.S. Bureau of Labor Statistics, compared with 3.4 percent in Dallas-Fort Worth and 2.9 percent in Austin.

A February report from Taylor Smith Consulting noted that the Houston economy had been in recovery mode after the collapse in oil prices and in the wake of Hurricane Harvey. However, one expert says Houston has now mostly bounced back from the economic slump.

Helping fuel Houston's economic recovery are initiatives like Houston Exponential, a new nonprofit designed to accelerate startup growth and, as a result, job growth. Formation of Houston Exponential was announced in October.

"The world calls Houston a knowledge capital because of the incredible concentration of ideas and innovation in our great city," Houston Mayor Sylvester Turner said in October. "Technology innovation and a vibrant startup community are key drivers to Houston's present as well as our future. Through [Houston Exponential], we will create new, high-paying jobs, grow our startup and technology community, make accessing entrepreneurship capital available to all of our citizens, improve our quality of life, and lead this culture of innovation that inspires each and every one of us."

------

This story originally appeared on CultureMap.

Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat.

Klemp observed that while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he says. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

The company has three core technologies currently being tested with some success, but the most promising is called WP1066, named for researcher Waldemar Priebe, "a rock star" in his native Poland, according to Klemp, who works at MD Anderson. Though Priebe came to the U.S. in the 1980s, he is still an adjunct professor at the University of Warsaw and conducts some of his trials in Poland because it's easier to get grant money there.

WP1066 uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The molecular compound that Priebe discovered affects STAT3 (signal transducer and activator of transcription), a transcription factor that encourages tumor development. In short, the active compound in WP1066 both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

WP1066 is demonstrating drug-like properties in trials at MD Anderson on glioblastoma, the aggressive brain cancer that recently took the life of the hospital's former president, John Mendelsohn, as well as John McCain and Beau Biden. It is also being tested against pancreatic cancer, one of the most virulent killers cancer doctors combat.

Priebe also created Annamycin, named for his oldest daughter, a first-line chemotherapy drug that fights Acute Myeloid Leukemia without the cardiotoxicity that can damage patients' hearts even as they beat their cancer.

WP1122 uses yet another mechanism to fight cancer.

"Most people don't know that morphine is essentially a modified version of heroin," Klemp explains.

The difference between the poppy-based drugs? Heroin can cross the blood-brain barrier. It's described as the dicetyl ester of morphine. WP1122 is the dicetyl ester of 2DG (2-Deoxyglucose), a glycolysis inhibitor, which works by overfilling tumor cells with fake glucose so that they can't consume the real glucose that makes them grow.

"The theory is, we could feed you so full of junk food that eventually you'd starve to death," Klemp elucidates. It can cross the blood-brain barrier and is metabolized slowly, meaning that it can be made into a drug in a way that 2DG cannot.

What's impressive about Moleculin is its diversity of drugs. Most companies have one drug that gets all or most of the attention. Moleculin has strong hopes for all three currently in trials.

"It's essentially multiple shots on the goal," says executive vice president and CFO Jonathan Foster.

Moleculin has 13 total employees, five of whom are based in Houston. An office in the Memorial Park area serves as a landing pad for employees and collaborators from around the world to get their work done when in Space City. The virtual office set-up works for the company because experts can stay in their home cities to get their work done. And that work is on its way to saving scores of lives.